225Ac-CONV-01-α is an alpha-radiolabeled monoclonal antibody targeting PSMA developed for the treatment of metastasized prostate cancer patients. This product is developed by Convergent Therapeutics, a partner of Aikido Pharma. The drug entered Phase I/II trial.
Target/Mechanism: PSMA
Leading Emitter: alpha particle (α)